Skip to content
The Policy VaultThe Policy Vault

EnbrelMedica

Ankylosing spondylitis

Initial criteria

  • age > 18 years
  • prescribed by or in consultation with a rheumatologist

Reauthorization criteria

  • patient has been established on therapy for at least 6 months
  • patient experienced a beneficial clinical response from baseline when assessed by at least one objective measure OR experienced an improvement in at least one symptom such as decreased pain or stiffness or improvement in function or activities of daily living

Approval duration

initial: 6 months; reauth: 1 year